Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor 纬

详细信息    查看全文

• 作者：Duo Zhao ; Zhicheng Zhu ; Dan Li ; Rihao Xu ; Tiance Wang ; Kexiang Liu
• 刊名：Biochemistry
• 出版年：2015
• 出版时间：November 17, 2015
• 年：2015
• 卷：54
• 期：45
• 页码：6806-6814
• 全文大小：493K
• ISSN：1520-4995

文摘

Cardiovascular disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Pioglitazone, the widely used thiazolidinedione, is shown to be efficient in the prevention of cardiovascular complications of T2DM. In this study, we report that pioglitazone inhibits CXCR7 expression and thus blocks chemotaxis in differentiated macrophage without perturbing cell viability or macrophage differentiation. In addition, pioglitazone-mediated CXCR7 suppression and chemotaxis inhibition occur via activating peroxisome proliferator-activated receptor 纬 (PPAR纬) but not PPAR伪 in differentiated macrophage. More importantly, pioglitazone therapy-induced PPAR纬 activation suppresses CXCR7 expression in human carotid atherosclerotic lesions. Collectively, our data demonstrate that pioglitazone suppresses CXCR7 expression to inhibit human macrophage chemotaxis through PPAR纬.